Cure51 Raises €15M in Seed Funding

Cure51, a Paris, France-based techbio company, raised €15M in Seed funding.


The round was led by Sofinnova Partners, with participation from Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel.

The company intends to use the funds to expand its development efforts.

Founded in March 2022 by Nicolas Wolikow and Simon Istolainen, alongside Gustave Roussy Institute (IGR, Paris – France), Leon Bérard Center (CLB, Lyon – France), Charité Universitätsmedizin (Berlin – Germany), Milan – Italy), and Vall d’Hebron (VHIO, Barcelona – Spain), Cure51 is a techbio company seeking to unlock the biological mechanisms responsible for exceptional survivors among cancer patients. Using its discovery platform empowered by computational modeling, the company aims to understand the biological mechanisms responsible for this exceptional survival by identifying and validating targets that can act on these interactions, leading to first in class treatments. This research involves the use of all relevant models (in silico, in vitro, in vivo, ex vivo) and the integration of existing literature and available databases, along with the engagement of its KOL community.